ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Triamcinolone Acetonide

Also written as “triamcinolone acetonide”, “SC CLS-TA” and “suprachoroidal CLS-TA”.

Its studies are mostly in Macular Edema · Uveitis · Diabetes Mellitus · Keloid · Pain, led by 12 companies.

Drug pageTriamcinolone Acetonide: every studyMany companies study it; this page follows only the 20 they lead. All 194 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 28, 201520 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clearside Biomedicalits history only70 open or runningphase 3since Oct 28, 2015Feb 5, 2013none ahead
Pacira BioSciencesits history only21 open or runningphase 3since Feb 13, 2024Feb 13, 2024Dec 2026phase 3 · NCT06269705
Sanofiits history only20 open or runningphase 3since Jun 26, 2006Jun 26, 2006none ahead
Alconits history only10 open or runningphase 3since Sep 19, 2007Sep 19, 2007none ahead
Biosplice Therapeuticsits history only10 open or runningphase 1since Oct 6, 2020Oct 6, 2020none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Oct 31, 2013Oct 31, 2013none ahead
Harrow11 open or runningphase 3since Sep 14, 2026Sep 14, 2026Dec 2026phase 3 · NCT07832552
Merckits history only10 open or runningphase 2since Jun 4, 2008Jun 4, 2008none ahead
Novartisits history only10 open or runningphase 3since Oct 19, 2005Oct 19, 2005none ahead
Oxularits history only10 open or runningphase 2since Aug 20, 2022Aug 20, 2022none ahead

Also a collaborator on its studies: QLT.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Harrow only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2026First study: phase 3 study in Postoperative Ocular InflammationFirst studyNCT07832552 · 250 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Postoperative Ocular InflammationNCT07832552

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

The one study Harrow leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07832552Postoperative Ocular Inflammation · United States3By invitationDec 2026250

How it is read

Names in the registry

  • “triamcinolone acetonide”, 4 entries
  • “Triamcinolone Acetonide”, 2 entries
  • “SC CLS-TA”, 2 entries
  • “suprachoroidal CLS-TA”, 2 entries
  • “Triamcinolone acetonide”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.